$STOK News

Stoke Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results

BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate.

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus

Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares

Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally

Canaccord Genuity Maintains Buy on Stoke Therapeutics, Raises Price Target to $60

BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

Stoke Therapeutics Files Prospectus For Flexible Offering Of Stock, Debt, Warrants, And Other Securities